Holen Sie sich die Stockscreener-App
68.05
1.52%
1.02
Handel nachbörslich:
68.70
0.65
+0.96%
Schlusskurs vom Vortag:
$67.03
Offen:
$67.83
24-Stunden-Volumen:
822.10K
Relative Volume:
0.55
Marktkapitalisierung:
$9.28B
Einnahmen:
$550.17M
Nettoeinkommen (Verlust:
$201.35M
KGV:
68.05
EPS:
1
Netto-Cashflow:
$232.07M
1W Leistung:
-7.45%
1M Leistung:
-6.10%
6M Leistung:
+27.84%
1J Leistung:
+55.15%
1-Tages-Spanne:
$67.24
$68.91
1-Wochen-Bereich:
$65.58
$73.53
52-Wochen-Spanne:
$40.87
$85.21
Doximity Inc Stock (DOCS) Company Profile
Firmenname
Doximity Inc
Sektor
Branche
Telefon
(650) 549-4330
Adresse
500 THIRD STREET, SUITE 510, SAN FRANCISCO
Vergleichen Sie DOCS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DOCS
Doximity Inc
|
68.05 | 12.55B | 550.17M | 201.35M | 232.07M | 1.00 |
|
VEEV
Veeva Systems Inc
|
287.38 | 47.15B | 2.97B | 809.93M | 1.33B | 4.8743 |
|
TEM
Tempus Ai Inc
|
91.91 | 15.61B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
HQY
Healthequity Inc
|
92.55 | 8.10B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
36.73 | 6.99B | 906.14M | -52.62M | 89.62M | -0.3621 |
Doximity Inc Stock (DOCS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-10-01 | Herabstufung | Goldman | Neutral → Sell |
| 2025-07-09 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-06-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-02-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-02-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-12-20 | Eingeleitet | Stephens | Equal-Weight |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-11-15 | Eingeleitet | Goldman | Neutral |
| 2024-11-14 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-11-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-11-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-11-08 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2024-10-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-08-09 | Hochstufung | Needham | Hold → Buy |
| 2024-07-18 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2024-04-25 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2024-01-02 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-08-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-08-09 | Herabstufung | Needham | Buy → Hold |
| 2023-08-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-10-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-24 | Eingeleitet | Evercore ISI | In-line |
| 2022-10-13 | Eingeleitet | BTIG Research | Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-28 | Eingeleitet | Berenberg | Buy |
| 2022-05-18 | Bestätigt | BofA Securities | Neutral |
| 2022-05-18 | Bestätigt | Goldman | Buy |
| 2022-05-18 | Bestätigt | Guggenheim | Buy |
| 2022-05-18 | Bestätigt | Jefferies | Buy |
| 2022-05-18 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Bestätigt | Needham | Buy |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-04 | Eingeleitet | BofA Securities | Neutral |
| 2022-02-11 | Eingeleitet | Goldman | Buy |
| 2021-12-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-11-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-11-10 | Bestätigt | Canaccord Genuity | Buy |
| 2021-11-10 | Bestätigt | Goldman | Neutral |
| 2021-11-10 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Bestätigt | Needham | Buy |
| 2021-11-10 | Bestätigt | Piper Sandler | Overweight |
| 2021-08-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-19 | Eingeleitet | Goldman | Neutral |
| 2021-07-19 | Eingeleitet | JP Morgan | Overweight |
| 2021-07-19 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-07-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-07-19 | Eingeleitet | Raymond James | Outperform |
| 2021-07-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-07-19 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Doximity Inc Aktie (DOCS) Neueste Nachrichten
Exit strategy if you’re trapped in Doximity Inc.Trade Performance Summary & Low Drawdown Investment Ideas - newser.com
Will Doximity Inc. stock recover faster than peersRate Hike & Weekly High Conviction Ideas - newser.com
Key metrics from Doximity Inc.’s quarterly dataTrade Analysis Report & Daily Growth Stock Investment Tips - newser.com
Is Doximity Inc. trending in predictive chart modelsWeekly Stock Recap & Real-Time Volume Surge Alerts - newser.com
Will earnings trigger a reversal in Doximity Inc.July 2025 Catalysts & Growth Focused Entry Point Reports - newser.com
Will Doximity Inc. Class stock announce a stock splitPrice Action & Risk Managed Investment Signals - newser.com
Using AI based signals to follow Doximity Inc.Weekly Investment Report & Precise Swing Trade Entry Alerts - newser.com
What catalysts could drive Doximity Inc. stock higherChart Signals & Stepwise Swing Trade Plans - newser.com
Does Doximity Inc. qualify in momentum factor screening2025 Price Action Summary & Momentum Based Trading Ideas - newser.com
Can machine learning forecast Doximity Inc. recoveryJuly 2025 Closing Moves & Safe Capital Growth Stock Tips - newser.com
How to read the order book for Doximity Inc.Quarterly Market Summary & Stepwise Entry/Exit Trade Alerts - newser.com
Is Doximity Inc. stock attractive for hedge funds2025 Price Momentum & Reliable Entry Point Trade Alerts - newser.com
ZoomInfo, Upstart, F5, Procore Technologies, and Doximity Shares Skyrocket, What You Need To Know - The Globe and Mail
Doximity’s SWOT analysis: digital health leader faces valuation hurdles By Investing.com - Investing.com Australia
Doximity’s SWOT analysis: digital health leader faces valuation hurdles - Investing.com India
Why Doximity Inc. Class stock appears on watchlistsWeekly Stock Recap & High Accuracy Buy Signal Tips - newser.com
Doximity, Inc. (DOCS) Stock Analysis: Understanding the 6.86% Potential Upside for Investors - DirectorsTalk Interviews
Doximity (DOCS): 3 Reasons We Love This Stock - The Globe and Mail
Applying sector rotation models to Doximity Inc.2025 Volatility Report & Fast Exit and Entry Trade Guides - newser.com
How to recover losses in Doximity Inc. stockPortfolio Return Summary & Daily Entry Point Trade Alerts - newser.com
Will Doximity Inc. Class stock beat growth indexesWeekly Market Report & Free High Return Stock Watch Alerts - newser.com
Doximity (NASDAQ:DOCS) Stock Price Down 5%Should You Sell? - MarketBeat
Doximity (DOCS) Valuation: Weighing Long-Term Gains Against Recent Share Price Drop - Yahoo Finance
Doximity's (DOCS) Underweight Rating Reiterated at JPMorgan Chase & Co. - MarketBeat
Doximity, Inc. $DOCS Shares Sold by Lmcg Investments LLC - MarketBeat
Here's Why Doximity (DOCS) Fell More Than Broader Market - sharewise.com
Doximity Shares Fall After Downgrade From JPMorgan - MarketScreener
Why Doximity (DOCS) Shares Are Trading Lower Today - Yahoo Finance
Doximity downgraded at J.P. Morgan on valuation and advertising concerns - MSN
When is the best time to exit Doximity Inc.Weekly Risk Summary & Step-by-Step Trade Execution Guides - newser.com
This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
JPMorgan Downgrades Doximity to Underweight From Neutral, $62 Price Target - MarketScreener
JPMorgan downgrades Doximity stock to Underweight on valuation concerns By Investing.com - Investing.com Australia
JPMorgan downgrades Doximity stock to Underweight on valuation concerns - Investing.com
Finanzdaten der Doximity Inc-Aktie (DOCS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.58%
0.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):